Dosing Strategy of Intravitreal Ranibizumab for Pathological Myopia Choroidal Neovascularization
Status:
Completed
Trial end date:
2018-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare the efficacy (times of injection, change of visual
acuity and Cva/ I) and safety (macular visual function and choroidal thickness) of different
dosing of ranibizumab intravitreal injection (1+PRN vs. 3+PRN) in treating with pathological
myopia choroidal neovascularization (PM-CNV).
Phase:
Phase 4
Details
Lead Sponsor:
Zhongshan Ophthalmic Center, Sun Yat-sen University